Adamant Health secures funding from Business Finland's Deep Tech Accelerator program for rapid market entry and targeted growth on international markets.

The Deep Tech Accelerator funding supports startups which have been founded to commercialize the latest research results and know-how. Based on more than 15 years of research, Adamant Health has developed the first, advanced precision technology able to measure the visible and invisible motor symptoms of Parkinson's disease. Our unique CE-marked data-analysis technology, based on surface electromyography (EMG), provides detailed and accurate symptom data, essential for supporting personalized treatment that can be continuously optimized.

The Deep Tech Accelerator funding will serve as a catalyst in accelerating our entry to selected European markets and drive our growth, particularly within our target customer segments including healthcare service providers and pharmaceutical companies.

Das Deep Tech Accelerator-Finanzierungspaket von Business Finland umfasst zwei Zeiträume mit einem Zuschuss von 400.000 EUR und einer Option auf ein Darlehen von 1.000.000 EUR.

For deep tech startups, who tend to have a much longer and riskier commercialization phase than other companies, the Business Finland Deep Tech Accelerator is a very important program to bring groundbreaking innovation to the market and disrupt entire industries.

Adamant Health is one of ten promising deep tech startups selected for the Deep Tech Accelerator program.

Parkinson's disease is the fastest growing neurological disorder globally. By enabling data-driven disease management, we are supporting earlier diagnosis and personalized treatment. For people with Parkinson’s disease this leads to a better control of the symptoms – improving their quality of life.

Read more about our measurement and analysis service.